Last reviewed · How we verify

Psychiatric treatment with escitalopram

Klinički Bolnički Centar Zagreb · Phase 1 active Small molecule

Psychiatric treatment with escitalopram is a Small molecule drug developed by Klinički Bolnički Centar Zagreb. It is currently in Phase 1 development. Also known as: Intervention II.

At a glance

Generic namePsychiatric treatment with escitalopram
Also known asIntervention II
SponsorKlinički Bolnički Centar Zagreb
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Psychiatric treatment with escitalopram

What is Psychiatric treatment with escitalopram?

Psychiatric treatment with escitalopram is a Small molecule drug developed by Klinički Bolnički Centar Zagreb.

Who makes Psychiatric treatment with escitalopram?

Psychiatric treatment with escitalopram is developed by Klinički Bolnički Centar Zagreb (see full Klinički Bolnički Centar Zagreb pipeline at /company/klini-ki-bolni-ki-centar-zagreb).

Is Psychiatric treatment with escitalopram also known as anything else?

Psychiatric treatment with escitalopram is also known as Intervention II.

What development phase is Psychiatric treatment with escitalopram in?

Psychiatric treatment with escitalopram is in Phase 1.

Related